ALK plus advanced NSCLC New ALK Inhibitor extends Sequence Options

被引：0
|
作者：
Freye, Reimund
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷 / 11期
关键词：
D O I：
10.1159/000494601
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：720 / 720
页数：1
相关论文
共 50 条
  • [41] Comparison of clinical and MRI features of brain metastases between ALK plus and ALK- NSCLC
    Ren, Xiaolu
    Zhang, Xuting
    Lei, Xiaoyan
    Ma, Weiqin
    Zhang, Ting
    Wang, Yuxiang
    Ren, Jiwei
    CANCER MEDICINE, 2024, 13 (11):
  • [42] Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK plus non-small cell lung cancer (NSCLC).
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA
    Gettinger, S.
    Bazhenova, L.
    Salgia, R.
    Langer, C.
    Gold, K.
    Rosell, R.
    Shaw, A.
    Weiss, G. J.
    Narasimhan, N. I.
    Dorer, D. J.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Camidge, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [44] Mechanisms of Acquired Resistance to the ALK Inhibitor Lorlatinib in ALK-Rearranged NSCLC Cell Lines
    Madsen, A.
    Jakobsen, K.
    Demuth, C.
    Sorensen, B.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2255 - S2255
  • [45] BRIGATINIB ALK and mutant EGFR inhibitor Treatment of NSCLC
    Gras, J.
    DRUGS OF THE FUTURE, 2015, 40 (05) : 287 - 292
  • [46] Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
    Noh, Ka-Won
    Sohn, Insuk
    Song, Ji-Young
    Shin, Hyun-Tae
    Kim, Yu-Jin
    Jung, Kyungsoo
    Sung, Minjung
    Kim, Mingi
    An, Sungbin
    Han, Joungho
    Lee, Se-Hoon
    Lee, Mi-Sook
    Choi, Yoon-La
    CLINICAL CANCER RESEARCH, 2018, 24 (17) : 4162 - 4174
  • [47] Distinct spatial distribution patterns of ALK-inhibitor naive versus ALK-inhibitor treated ALK-positive NSCLC brain metastases
    Cheunkarndee, Tia
    Ganem, Paola
    Marrone, Kristen A.
    Murray, Joseph C.
    Feliciano, Josephine L.
    Hann, Christine L.
    Scott, Susan C.
    Ettinger, David
    Anagnostou, Valsamo
    Forde, Patrick M.
    Brahmer, Julie R.
    Levy, Benjamin P.
    Lam, Vincent
    Kamson, David O.
    CANCER RESEARCH, 2023, 83 (07)
  • [48] Exo-ALK Proof of Concept: Exosomal Analysis of ALK Alterations in Advanced NSCLC Patients
    Rolfo, Christian
    Laes, Jean Francois
    Reclusa, Pablo
    Valentino, Anna
    Lienard, Maxime
    Gil-Bazo, Ignacio
    Malapelle, Umberto
    Sirera, Rafael
    Rocco, Danilo
    Van Meerbeeck, Jan
    Pauwels, Patrick
    Peeters, Marc
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S844 - S845
  • [49] Alectinib: A Review in Advanced, ALK-Positive NSCLC
    Julia Paik
    Sohita Dhillon
    Drugs, 2018, 78 : 1247 - 1257
  • [50] Ceritinib: a Review in ALK-Positive Advanced NSCLC
    Emma D. Deeks
    Targeted Oncology, 2016, 11 : 693 - 700
12345